Δ9 tetrahydrocannabinol (Δ9 THC) solution metered dose inhalers and methods of use
AssigneeVirginia Commonwealth University
InventorsJoanne Peart, Peter R. Byron, Aron H. Lichtman, Billy R. Martin
Life of this patent
Estimating the term…
Abstract
The present invention provides therapeutic formulations for solutions of Δ9-tetrahydrocannabinol (Δ9 THC) to be delivered by metered dose inhalers. The formulations, which use, non-CFC propellants, provide a stable aerosol-deliverable source of Δ9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy-muscle spasticity; pain; anorexia associated with AIDS wasting syndrome, epilepsy; glaucoma; bronchial asthma; and mood disorders.
Claims16
A method of administering a pharmaceutically effective dose of aerosolized Δ9 tetrahydrocannabinol to a patient, comprising the steps of:
- providing a solution comprising a pharmaceutically acceptable form of Δ9 tetrahydrocannabinol (THC) in a hydrofluoroalkane, said solution having not more than 15% w/w of a pharmaceutically acceptable solvent;
- aerosolizing the THC solution to provide respirable droplets comprising THC wherein at least 20% of the mass of the respirable droplets comprise droplets having an aerodynamic diameter of less than 5.8 μm;
- administering a pharmaceutically effective does of said respirable droplets to a patient's lungs.
A method of administering a pharmaceutically effective dose of aerosolized Δ9 tetrahydrocannabinol to a patient, comprising the steps of:
- providing a solution comprising a pharmaceutically acceptable form of tetrahydrocannabinol (THC) in a hydrofluoroalkane, said solution having not more than 15% w/w of a pharmaceutically acceptable solvent;
- aerosolizing the solution to provide respirable droplets comprising THC wherein at least 20% of the mass of the respirable droplets comprise droplets having an aerodynamic diameter of less than 5.8 μm;
- administering a pharmaceutically effective dose of said respirable droplets to a patient's lungs to achieve brain levels of THC that are substantially the same as blood levels of THC in said patient.
Dependencies are inferred from the claim text.